One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Relmada Therapeutics, Inc.
RLMD · NCM · Healthcare · Biotechnology
Current price
$3.36
52-week range
$1.80 - $8.00
Market cap
$358.41M
Balance sheet
Healthy
-42.34x Concerning
Net cash $217.73M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -55.7% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 3.2% (peer median: 23.1%).
What this company does
Relmada Therapeutics, Inc.
Relmada Therapeutics is a company that develops new medicines for serious diseases like bladder cancer and rare genetic disorders. Their main money source is from creating and testing these experimental drugs, with the hope that successful ones will eventually be sold. This matters because if their drug trials are successful, they could help many patients and generate significant revenue.
How the company got here
Relmada Therapeutics was founded in 2004 and is a clinical-stage biotechnology company headquartered in Coral Gables, Florida. The company has focused on developing therapies for central nervous system (CNS) disorders and oncology. While it has explored various drug candidates over the years, including treatments for major depressive disorder, some of these programs have faced setbacks, leading the company to re-evaluate its strategic direction. Relmada is now concentrating its efforts on a more focused pipeline of potential high-value assets.
What it actually does
Relmada Therapeutics is a biotechnology company that works on developing new medicines, particularly for diseases affecting the brain and nervous system, as well as for certain types of cancer. They are in the 'clinical-stage,' which means their potential drugs have moved past initial lab tests and are being tested in human trials to see if they are safe and effective. The company doesn't sell any products yet; its main work involves research and development to bring new treatments to patients.
NDV-01 for Non-Muscle Invasive Bladder Cancer (NMIBC)
This is Relmada's main focus in oncology. NDV-01 is a special formulation of two chemotherapy drugs, gemcitabine and docetaxel, designed to be delivered directly into the bladder (intravesical therapy). The goal is to keep the drugs in the bladder for a longer time, providing a consistent local treatment for aggressive forms of non-muscle invasive bladder cancer (NMIBC). This approach aims to be more convenient for doctors and patients than current methods, and it's currently in Phase 3 clinical trials, which are large-scale studies to confirm its effectiveness and safety before seeking approval from regulatory agencies.
Sepranolone for Compulsion-Related Disorders
Sepranolone is a different type of drug candidate, a neurosteroid, that Relmada is developing for conditions involving compulsive behaviors. This includes potential treatments for Prader-Willi syndrome, Tourette syndrome, and excessive tremor. The drug works by affecting a specific part of the brain's signaling system (GABAergic activity). Relmada is advancing Sepranolone toward Phase 2 clinical trials, which are designed to further evaluate its safety and effectiveness in patients with these specific neurological and behavioral conditions.
What management is betting on now
Relmada's current strategy centers on advancing its two main drug candidates, NDV-01 and Sepranolone, through their respective clinical development pathways. The company is emphasizing disciplined execution, aiming for durable efficacy, favorable safety profiles, and ease of administration for its therapies. Management is focused on clear regulatory pathways and broad clinical adoption for these programs. They are also exploring strategic opportunities to maximize shareholder value, which may include partnerships or other transactions, especially after facing challenges with previous drug development programs.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-12.91M
Diluted EPS
-0.11
Operating cash flow
$-9.61M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-19.05M
Diluted EPS
-0.22
Operating cash flow
$-15.07M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-19.87M
Diluted EPS
-0.27
Operating cash flow
$-14.60M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-10.09M
Diluted EPS
-0.30
Operating cash flow
$-6.72M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-9.87M
Diluted EPS
-0.30
Operating cash flow
$-6.40M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-17.56M
Diluted EPS
-0.58
Operating cash flow
$-18.07M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-18.66M
Diluted EPS
-0.62
Operating cash flow
$-8.80M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-21.73M
Diluted EPS
-0.72
Operating cash flow
$-16.66M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $3.36
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $217.7M - more cash than debt. Interest coverage -42.3x.
Net debt
$-217.73M
Interest coverage
-42.34x
Relmada Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
RLMD
BASELINE
Relmada Therapeutics, Inc.
Total debt $0.00 Interest coverage -42.34x This is the baseline the peer rows are being compared against.
Total debt $300.74M Interest coverage 1.26x This peer still has a real interest-payment cushion, while RLMD does not.
Total debt $17.11M Interest coverage -14.78x Neither company has much profit cushion over interest right now.
Total debt $688.32M Interest coverage 5.51x This peer still has a real interest-payment cushion, while RLMD does not.
Total debt $1.29M Interest coverage -1,499.77x Neither company has much profit cushion over interest right now.
What you should know
The case for and against RLMD
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -55.7% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 3.2% (peer median: 23.1%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-8.20x
P/B
1.74x
P/S
—
EV/EBITDA
—
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-55.7%
ROA
-32.4%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
29.52x
Quick ratio
29.34x
Total debt
$0.00
Total cash
$217.73M
Growth
How the business has been compounding
Revenue TTM
$3.17K
Revenue 5Y CAGR
—
EPS TTM
-0.91
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-45.99M
Free CF TTM
$-45.79M
FCF margin
-1,446,209.3%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—